

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2021 May 7; 27(17): 1847-2053



### EVIDENCE REVIEW

- 1847** Pancreatic adenocarcinoma: Beyond first line, where are we?  
*Cherri S, Noventa S, Zaniboni A*

### REVIEW

- 1864** Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect  
*Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK*
- 1883** Repurposing metformin for the treatment of gastrointestinal cancer  
*Cunha Júnior AD, Bragagnoli AC, Costa FO, Carnevalheira JBC*
- 1905** Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment  
*Chinnici CM, Russell G, Bulati M, Miceli V, Gallo A, Busà R, Tinnirello R, Conaldi PG, Iannolo G*

### MINIREVIEWS

- 1920** Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions  
*Gubatan J, Levitte S, Patel A, Balabanis T, Wei MT, Sinha SR*
- 1936** Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer  
*Petrov MS*
- 1943** BRCA mutated pancreatic cancer: A change is coming  
*Rosen MN, Goodwin RA, Vickers MM*
- 1959** Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond  
*Shengir M, Elgara M, Sebastiani G*

### ORIGINAL ARTICLE

#### Basic Study

- 1973** S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis  
*Dong XH, Dai D, Yang ZD, Yu XO, Li H, Kang H*
- 1993** Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis  
*Wang B, Sun X, Huang KJ, Zhou LS, Qiu ZJ*

**Retrospective Study**

- 2015** Prediction of microvascular invasion in solitary hepatocellular carcinoma  $\leq 5$  cm based on computed tomography radiomics

*Liu P, Tan XZ, Zhang T, Gu QB, Mao XH, Li YC, He YQ*

- 2025** Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study

*Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ*

**Observational Study**

- 2039** Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact

*Detlie TE, Lindström JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Abhinav Vasudevan, Bachelor of Medicine, MPH, PhD, FRACP, Advanced Inflammatory Bowel Disease Fellow, Mayo Clinic, 200 1st Street SW, Rochester, MN 55902, United States. [vasudevan.abhinav@mayo.edu](mailto:vasudevan.abhinav@mayo.edu)

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for WJG as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2019 is 7.1 and Scopus CiteScore rank 2019: Gastroenterology is 17/137.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yan-Jie Ma*; Production Department Director: *Xiang Li*; Editorial Office Director: *Ze-Mao Gong*.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski, Subrata Ghosh

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

May 7, 2021

**COPYRIGHT**

© 2021 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Basic Study

# Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis

Bin Wang, Xing Sun, Ke-Jian Huang, Li-Sheng Zhou, Zheng-Jun Qiu

**ORCID number:** Bin Wang 0000-0002-2971-773X; Xing Sun 0000-0001-5256-9758; Ke-Jian Huang 0000-0001-9093-4138; Li-Sheng Zhou 0000-0002-4498-8765; Zheng-Jun Qiu 0000-0002-8318-847X.

**Author contributions:** Qiu ZJ and Wang B conceived and supervised the study and wrote the manuscript; Wang B performed most of the experiments and data analyses; Sun X, Zhou LS, and Huang KJ performed Western blot experiments and data analysis; Zhou LS took part in the discussions; all the authors discussed the results, commented on the manuscript, and approved the final version of the article.

**Supported by** National Natural Science Foundation of China, No. 81974372.

**Institutional review board statement:** The study was reviewed and approved by the Medical Ethics Committee of Shanghai First People's Hospital Institutional Review Board (No. 2019KY065).

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Animal Ethics

Bin Wang, Xing Sun, Ke-Jian Huang, Li-Sheng Zhou, Zheng-Jun Qiu, Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China

**Corresponding author:** Zheng-Jun Qiu, MD, Chief Doctor, Director, Surgeon, Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Shanghai 200080, China. [qiuwjdoctor@sina.com](mailto:qiuwjdoctor@sina.com)

## Abstract

### BACKGROUND

Previous studies have suggested that long non-coding RNAs (lncRNA) TP73-AS1 is significantly upregulated in several cancers. However, the biological role and clinical significance of TP73-AS1 in pancreatic cancer (PC) remain unclear.

### AIM

To investigate the role of TP73-AS1 in the growth and metastasis of PC.

### METHODS

The expression of lncRNA TP73-AS1, miR-128-3p, and *GOLM1* in PC tissues and cells was detected by quantitative real-time polymerase chain reaction. The bioinformatics prediction software ENCORI was used to predict the putative binding sites of miR-128-3p. The regulatory roles of TP73-AS1 and miR-128-3p in cell proliferation, migration, and invasion abilities were verified by Cell Counting Kit-8, wound-healing, and transwell assays, as well as flow cytometry and Western blot analysis. The interactions among TP73-AS1, miR-128-3p, and *GOLM1* were explored by bioinformatics prediction, luciferase assay, and Western blot.

### RESULTS

The expression of TP73-AS1 and miRNA-128-3p was dysregulated in PC tissues and cells. High TP73-AS1 expression was correlated with a poor prognosis. TP73-AS1 silencing inhibited PC cell proliferation, migration, and invasion *in vitro* as well as suppressed tumor growth *in vivo*. Mechanistically, TP73-AS1 was validated to promote PC progression through *GOLM1* upregulation by competitively binding to miR-128-3p.

### CONCLUSION

Our results demonstrated that TP73-AS1 promotes PC progression by regulating

Committee of Shanghai First People's Hospital (No. 2019 AW050).

**Conflict-of-interest statement:** The authors declare no conflicts of interest for this work.

**Data sharing statement:** The authors agree with the data sharing.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report's scientific quality classification**

Grade A (Excellent): A  
Grade B (Very good): B, B, B  
Grade C (Good): C  
Grade D (Fair): 0  
Grade E (Poor): 0

**Received:** December 14, 2020

**Peer-review started:** December 14, 2020

**First decision:** February 11, 2021

**Revised:** February 24, 2021

**Accepted:** March 24, 2021

**Article in press:** March 24, 2021

**Published online:** May 7, 2021

**P-Reviewer:** Koustas E, Mikulic D,

the miR-128-3p/GOLM1 axis, which might provide a potential treatment strategy for patients with PC.

**Key Words:** Pancreatic cancer; Long non-coding RNA; TP73-AS1; miR-128-3p; GOLM1

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** In this study, the expression level of TP73-AS1 in pancreatic cancer (PC) was measured and its clinical significance was assessed. *In vitro* and *in vivo* experiments were performed to determine the roles of TP73-AS1 in the progression and development of PC. Moreover, the underlying molecular mechanisms were also illustrated, which could provide a novel therapeutic target for patients with PC.

**Citation:** Wang B, Sun X, Huang KJ, Zhou LS, Qiu ZJ. Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis. *World J Gastroenterol* 2021; 27(17): 1993-2014

**URL:** <https://www.wjgnet.com/1007-9327/full/v27/i17/1993.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v27.i17.1993>

## INTRODUCTION

Pancreatic cancer (PC) is the fourth most frequent cause of cancer-related deaths with an extremely poor prognosis, especially in patients with advanced-stage PC [1,2]. Although standard treatments have been improved in recent years, the effectiveness of these treatments was still limited and surgical resection was the only chance to obtain curative treatment[2,3]. Hence, it is necessary to seek for new treatment to optimize therapeutic approaches.

Long non-coding RNAs (lncRNAs) are small endogenous non-coding RNAs whose lengths are larger than 200 nucleotides. lncRNAs have the capacity to regulate various biological processes such as tumor initiation, growth, metastasis, chemoresistance, and radioresistance by directly binding to partially complementary sequences in their target genes[4-7]. Moreover, emerging evidence has revealed that lncRNAs could play crucial roles in the progression of PC[8,9]. lncRNA-BX111 was upregulated in pancreatic cancer and high BX111 expression was correlated with advance tumor-node-metastasis (TNM) stage, lymphatic invasion, and distant metastasis, as well as poor clinical prognosis in patients with PC[10]. Further investigation revealed that BX111 contributed to metastasis and progression of PC by regulating expression of ZEB1 and its downstream proteins E-cadherin and MMP2[10]. PVT1 was identified as a regulator of gemcitabine sensitivity with a genome-wide and piggyBac transposon-based genetic screening platform[11]. Therefore, lncRNAs may be new biological markers for disease diagnosis and could be taken as new drug targets, which would provide a new strategy for PC.

Dysregulation of TP73-AS1 has been identified in several human cancer types, including glioma, hepatocellular carcinoma, and non-small cell lung cancer[12-14]. However, little is known about the expression pattern and biological roles of TP73-AS1 in PC. In this study, the expression level of TP73-AS1 in PC was measured and its clinical significance was assessed. *In vitro* and *in vivo* experiments were performed to determine the roles of TP73-AS1 in the progression and development of PC. Further investigation indicated that the 3' untranslated region (UTR) of *GOLM1* harbors a functional response element for miR-128-3p. Besides, miR-128-3p-3p could abrogate TP73-AS1-mediated expression of *GOLM1*, which suggested that TP73-AS1 could act as a molecular sponge to decrease miR-128-3p expression, thereby resulting in partial abolition of the translational repression of its target gene *GOLM1* in PC cells. Therefore, we hope that the underlying molecular mechanisms of TP73-AS1 could provide a novel therapeutic target for patients with PC.

Shimada S, Tantau AI

**S-Editor:** Fan JR**L-Editor:** Wang TQ**P-Editor:** Wang LL

## MATERIALS AND METHODS

### *Clinical specimens*

A total of 116 clinical PC tissues and corresponding normal tissues from surgical resection were collected at Shanghai General Hospital of Shanghai Jiao Tong University between April 2007 and July 2010. PC was diagnosed by pathological examinations. Patients were excluded if they received any treatments such as chemotherapy, radiotherapy, or molecular targeted therapy prior to surgery. All patients provided informed written consent prior to the use of these clinical materials for research purpose. This study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Shanghai First People's Hospital (No. 2014-07DF), School of Medicine, Shanghai Jiaotong University (Shanghai, China). All human tissues were immediately frozen in liquid nitrogen until being used.

### *Cell lines and transfection*

Human PC cell lines (SW1990, PANC-1, BXPC-3, AsPc-1, and Capan-1) and human pancreatic duct epithelial cell line (H6C7) were obtained from the Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA, United States) supplemented with 10% fetal bovine serum (FBS, Invitrogen), 100 U/mL penicillin, and 100 µg/mL streptomycin (Hyclone, South Logan, UT, United States) in a humidified incubator (5% CO<sub>2</sub>) at 37 °C. Small interfering RNAs (siRNAs) targeting TP73-AS1 (si-TP73-AS1#1, si-TP73-AS1#2, and si-TP73-AS1#3) and negative control (si-control) were purchased from GenePharma (Shanghai, China). MiR-128-3p, miR-NC, anti-miR-128-3p, and anti-miR-NC were obtained from Thermofisher. Cell transfection was performed using FuGENE HD Transfection Reagent (Roche, United States) according to the manufacturer's instructions.

### *Quantitative reverse transcription-polymerase chain reaction*

Total RNA was isolated using TRIzol reagent (Invitrogen) from PC tissues and cell lines. RNA was reversely transcribed into cDNA using the PrimeScript™RT reagent Kit with gDNA Eraser (TakaRa, Dalian, China). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using FastStart Universal SYBR Green Master (Roche, Basel, Switzerland) on a Bio-Rad RT-PCR cycler (Bio-Rad, Hercules, United States). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and small RNA RNU6B (U6) were used as the internal controls for lncRNA/mRNA and miRNAs, respectively. Relative expression values of genes were analyzed by the 2<sup>-ΔΔCt</sup> method.

### *Cell proliferation, colony formation, and apoptosis assays*

For cell proliferation assay, cells were plated into 96-well plates with four replicate wells per group and then incubated with 10 µL of CCK-8 reagent (Dojindo, Kumamoto, Japan). The absorbance was measured at 450 nm with a microplate reader (Bio-Tek, Winooski, United States) 2 h later. For colony formation assay, approximately 600 cells were plated into 6-well plates with three replicates. Cells were fixed with 10% formaldehyde and stained with 0.5% crystal violet 14 d later. Cell apoptosis was detected using Annexin-V-fluorescein isothiocyanate apoptosis detection kit (BD, Franklin Lakes, United States) according to the manufacturer's instructions. The apoptosis rate of cells was measured on a BD FACS Aria™ II flow cytometer (BD).

### *Transwell assay*

Cell migration and invasion were evaluated using the Boyden chambers (Millipore; Merck KGaA, Germany) with an 8 mm pore size. Briefly, a total of 2 × 10<sup>4</sup> cells in 100 µL serum-free medium were transferred into the upper chamber, and the lower chamber was filled with medium containing 10% FBS. After 24 h incubation, cells were fixed with 10% formaldehyde for 15 min and stained with 0.5% crystal violet for 20 min at room temperature. The migrated cells were counted under an X71 inverted microscope in six randomly selected fields and captured using a microscope (Nikon). The invasion assay was performed in the same way as the migration assay did except that the inserts were pre-coated with Matrigel (BD).

### *Luciferase reporter assay*

The putative miR-128-3p binding sites in TP73-AS1 and GOLM1 3'UTR were synthesized and inserted into pMIR-REPORT™ miRNA Expression Reporter Vector

(ThermoFisher). Their corresponding mutants were generated using MutanBEST Kit (TaKaRa). AsPc-1 and Capan-1 cells were co-transfected with these reporter plasmids and pMIR-REPORT  $\beta$ -gal, miR-128-3p mimics, or miR-128-3p inhibitors using Lipofectamine 3000 (Invitrogen). Luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega, WI, United States) 48 h after the transfection.

### RNA immunoprecipitation assay

PANC-1 and ASPC-1 cells transfected with miR-NC or miR-128-3p were harvested with revised importance-performance analysis lysis buffer (Cell Signaling Technology, Danvers, MA, United States) containing a proteinase inhibitor cocktail (Roche, IN, United States). The lysates were incubated with magnetic beads conjugated with human anti-Ago2 antibody and normal rabbit immunoglobulin G. Then RNA was isolated from the mixture with TRIzol reagent for qRT-PCR analysis.

### Western blot analysis

Western blot was performed as we previously described[15]. The primary antibodies used in this study are listed as following: Anti-GOLM1 (H00051280-PW1, Abnova, Taiwan), anti-GAPDH (#10494-1-AP, Proteintech, IL, United States), anti-E-cadherin (14-3249-82, CST, United States), anti-N-cadherin (MA1-91128, CST, United States), anti-Vimentin (PA5-27231, CST, United States), anti-Caspase-3 (700182, CST, United States), and anti-Bcl-2 (MA5-11757, CST, United States).

### In vivo xenograft experiment

All animal experiments were performed in compliance to institutional guidelines approved by the Use Committee for Animal Care and this study was approved by the Ethics Committees of Shanghai First People's Hospital of Shanghai Jiao Tong University (approval No. 201804SF). Female BALB/c-nude mice (4–6 wk of age) were purchased from Shanghai SJA Laboratory Animal Company (Shanghai, China) and maintained under specific pathogen free conditions. Capan-1 cells ( $1 \times 10^7$ ; transfected with si-control or si-TP73-AS1#1) mingled with 100  $\mu$ L serum-free medium were injected subcutaneously into the flanks of the nude mice. All mice were sacrificed 4 wk after injection and then tumors were isolated and photographed. Tumor volumes were calculated using the formula  $\text{length} \times \text{width}^2/2$  and tumor weights were measured. For tail vein injection,  $1 \times 10^6$  cells in serum-free medium were injected into 6 wk-old BALB/c-nude mice *via* the tail vein. Five weeks after injection, all mice were sacrificed and lung tissues were finally embedded with paraffin and subjected to hematoxylin and eosin (H&E) staining.

### Statistical analysis

Data are shown as the mean  $\pm$  SD. The differences between groups were analyzed by Student's *t*-test or Chi-square test. The cumulative overall survival was calculated using the Kaplan-Meier method, and the log-rank test was used to analyze differences in the survival times. Data were analyzed using GraphPad software 7.0. *P* < 0.05 was considered significant.

## RESULTS

### TP73-AS1 is upregulated in PC and associated with a poor prognosis

To explore the roles of TP73-AS1 in PC, we first detected the expression of TP73-AS1 in the human pancreatic duct epithelial cell line (H6C7) and five PC cell lines by qRT-PCR. Our data indicated that TP73-AS1 expression was higher in all PC cell lines than in H6C7, especially in AsPc-1 and Capan-1 cells (Figure 1A). Then the expression of TP73-AS1 in 116 pairs of PC tissues and adjacent non-cancerous tissues was measured, and the results revealed that TP73-AS1 expression was significantly increased in PC tissues compared to the corresponding non-cancerous tissues (Figure 1B and C). Furthermore, it was shown that in the tissue samples of stages I and II PC patients, the expression levels of TP73-AS1 were lower than those in stage III PC patients (Figure 1D). Moreover, the associations between TP73-AS1 expression and the clinicopathological characteristics in PC patients were analyzed. The results suggested that increased TP73-AS1 expression was significantly correlated with tumor size, vessel infiltration, and TNM stage. Besides, no correlation was found between TP73-AS1 expression and other clinical pathological features (Table 1). Kaplan-Meier

**Table 1 Relationship between TP73-AS1 expression and clinicopathological features**


| Characteristic        | (n)     | TP73-AS1 expression |                 | P value |
|-----------------------|---------|---------------------|-----------------|---------|
|                       | n = 116 | Low expression      | High expression |         |
| Age                   |         |                     |                 | 0.7101  |
| < 60                  | 65      | 32                  | 33              |         |
| ≥ 60                  | 51      | 23                  | 28              |         |
| Gender                |         |                     |                 | 0.7026  |
| Male                  | 74      | 34                  | 40              |         |
| Female                | 42      | 21                  | 21              |         |
| Tumor differentiation |         |                     |                 | 0.5723  |
| Poor                  | 69      | 31                  | 38              |         |
| Middle and well       | 47      | 24                  | 23              |         |
| Tumor size            |         |                     |                 | 0.008   |
| ≤ 2 cm                | 48      | 31                  | 17              |         |
| > 2 cm                | 68      | 26                  | 42              |         |
| Tumor site            |         |                     |                 | 0.4555  |
| Head                  | 64      | 28                  | 36              |         |
| Body                  | 52      | 27                  | 25              |         |
| Vessel infiltration   |         |                     |                 | 0.001   |
| Negative              | 82      | 47                  | 35              |         |
| Positive              | 34      | 8                   | 26              |         |
| Lymph node metastasis |         |                     |                 | 0.5526  |
| No                    | 78      | 35                  | 43              |         |
| Yes                   | 38      | 20                  | 18              |         |
| TNM stage             |         |                     |                 | 0.0008  |
| I-II                  | 84      | 48                  | 36              |         |
| III                   | 32      | 7                   | 25              |         |

TNM: Tumor-node-metastasis.

survival results suggested that patients with higher TP73-AS1 expression had a shorter overall survival than those with lower TP73-AS1 expression (Figure 1E). These data indicated that TP73-AS1 might play a vital role in the progression of PC.

### ***LncRNA TP73-AS1 is required for efficient PC cell proliferation, migration, and invasion***


In order to assess the biological functions of TP73-AS1, we knocked down TP73-AS1 by transfecting specific siRNAs in AsPc-1 and Capan-1 cells, which have higher endogenous TP73-AS1 expression. The knockdown efficacy was confirmed by qRT-PCR analysis. The expression of TP73-AS1 was markedly decreased in AsPc-1 and Capan-1 cells after transfecting with siRNAs targeting TP73-AS1 (Figure 2A). CCK-8 (Figure 2B) and colony formation assay (Figure 2C) showed that knockdown of TP73-AS1 in PC cells markedly restrained cell proliferation. Furthermore, cell apoptosis was highly promoted by depletion of TP73-AS1 in AsPc-1 and Capan-1 cells (Figure 2D). In addition, in the transwell assay, TP73-AS1 silencing could effectively impede the invasive ability of PC cells (Figure 2E and F). These data revealed that TP73-AS1 acts as an oncogene and depletion of TP73-AS1 inhibits PC cell growth and invasion *in vitro*.




**Figure 1** Aberrantly expressed TP73-AS1 in pancreatic cancer cells and tissues. A: TP73-AS1 expression in pancreatic cancer (PC) cell lines and an immortalized human pancreatic duct epithelial cell (H6C7) detected by quantitative real-time polymerase chain reaction; B: The relative expression of TP73-AS1 in 116 paired PC tissues and adjacent non-tumor tissues; C: TP73-AS1 is highly expressed in collected PC tissues; D: The different expression of TP73-AS1 between tumor-node-metastasis (TNM) stage I-II; and TNM stage III; E: Kaplan-Meier analysis of the overall survival in patients with PC based on the levels of TP73-AS1 expression. <sup>a</sup> $P < 0.05$ ; <sup>b</sup> $P < 0.01$ .

### LncRNA TP73-AS1 functions as a competing endogenous RNA and sponges miR-128-3p in PC cells

Accumulating evidence suggests that lncRNAs could bind to miRNAs and function as a molecular sponge in the tumorigenesis of various cancers[4]. To elucidate the





**Figure 2 Knockdown of TP73-AS1 suppresses cell proliferation and invasion *in vitro*.** A: Quantitative real-time polymerase chain reaction analysis of TP73-AS1 expression in AsPc-1 and Capan-1 cells transfected with si-control and small interfering RNAs targeting TP73-AS1; B: CCK-8 proliferation assay in pancreatic cancer cells transfected with si-control, si-TP73-AS1#1, or si-TP73-AS1#3; C: Colony formation assay in AsPc-1 and Capan-1 cells transfected with si-control, si-TP73-AS1#1, or si-TP73-AS1#3; D: Role of TP73-AS1 on AsPc-1 and Capan-1 cells apoptosis checked by flow cytometry assay; E and F: Effect of TP73-AS1 silencing on the migration and invasion ability of AsPc-1 (E) and Capan-1 (F) cell determined by transwell assay. <sup>a</sup> $P < 0.05$ ; <sup>b</sup> $P < 0.01$ .

underlying mechanism of TP73-AS1 involved in PC progression, the potential target miRNAs of TP73-AS1 were forecasted with bioinformatics analysis software (<http://starbase.sysu.edu.cn>). Among these potential targets, miR-128-3p was chosen for further study because it had been validated as a tumor suppressor in PC (Figure 3A)[16]. Dual-luciferase reporter assay was used to validate the relationship between TP73-AS1 and miR-128-3p. The activity of the wild-type luciferase reporter gene was significantly reduced following transfection with miR-128-3p mimics, whereas the activity of the reporter gene containing the mutant sequence showed no significant change, which indicated that TP73-AS1 could bind to the specific sites of miR-128-3p (Figure 3B). Moreover, anti-Ago2 RNA immunoprecipitation in AsPc-1 and Capan-1 cells transiently overexpressing miR-128-3p could significantly increase the amount of TP73-AS1 (Figure 3C), which could further validate their binding potential. The expression of miR-128-3p was significantly increased in PC cells transfected with si-TP73-AS1#1 and si-TP73-AS1#3 (Figure 3D). Then, we measured miR-128-3p expression level and the relationship between TP73-AS1 and miR-128-3p expression in PC tissues. Interestingly, qRT-PCR assay showed that the miR-128-3p level was remarkably reduced in PC tissues (Figure 3E) and the endogenous miR-128-3p level was negatively correlated with TP73-AS1 in PC tissues (Figure 3F). These results suggested that TP73-AS1 might function as a competing endogenous RNA (ceRNA) for miR-128-3p.

### ***MiR-128-3p-3p inhibits pancreatic cell proliferation, migration, and invasion***

MiR-128-3p was reported to be a tumor suppressor in several cancers, including PC[16,17]. But its effects in the progression of PC are largely unknown. To explore the roles of miR-128-3p in PC cell growth and mobility, miR-128-3p mimics were transfected in AsPc-1 and Capan-1 cells (Figure 4A). CCK-8 (Figure 4B) and colony formation assays (Figure 4C) revealed that miR-128-3p had significant negative regulation effects on the ability of cell proliferation in AsPc-1 and Capan-1 cells. Flow cytometry assay indicated that overexpression of miR-128-3p increased the number of apoptotic cells both in AsPc-1 and Capan-1 cells (Figure 4D). Meanwhile, transwell assays demonstrated that miR-128-3p overexpression significantly restrained PC cell migration and invasion (Figure 4E and F). Considering the downregulation of miR-128-3p in PC tissues, our results manifested that miR-128-3p could act as a tumor suppressor by regulating PC cell proliferation and invasion.




### ***Inhibition of miR-128-3p partly reverses regulatory effects induced by depletion of TP73-AS1***


To determine if TP73-AS1 knockdown could exert anti-proliferation and anti-metastasis function by mediating miR-128-3p, anti-miR-128-3p was transfected into AsPc-1 and Capan-1 cells after TP73-AS1 silencing. Functional experiments demonstrated that the TP73-AS1-mediated pro-proliferation (Figure 5A) and anti-apoptosis (Figure 5B) effect was dramatically abrogated by anti-miR-128-3p transfection in TP73-AS1 silencing PC cells. In addition, the inhibitory effects of TP73-AS1 silencing on cell metastasis were rescued by anti-miR-128-3p transfection (Figure 5C and D). Moreover, epithelial-mesenchymal transition (EMT)-related proteins were detected by Western blot. Consistent with the functional assays above, the results showed that TP73-AS1 could regulate EMT-related proteins by regulating miR-128-3p (Figure 5E). All these data indicated that TP73-AS1 is involved in PC progression, at least partly through miR-128-3p.

### ***LncRNA TP73-AS1 regulates GOLM1 expression by competing for miR-128-3p-3p***

Since TP73-AS1 was demonstrated to bind to miR-128-3p, we assessed whether TP73-AS1 could indirectly affect the target gene of miR-128-3p by serving as a ceRNA. Based on online bioinformatics analysis, GOLM1 3'UTR was found to possess a putative recognition site for miR-128-3p (Figure 6A). The luciferase reporter assay was carried out and the results showed that the luciferase activity of plasmid carrying GOLM1 3'UTR-WT was significantly decreased by transfecting miR-128-3p mimics both in AsPc-1 and Capan-1 cells (Figure 6B). However, these effects were abolished when the binding sequences were mutated. Transfecting miR-128-3p mimics led to a significant decrease of GOLM1 mRNA and protein expression in AsPc-1 and Capan-1 cells (Figure 6C). To further explore the correlation between TP73-AS1 and GOLM1, the mRNA and protein expression of GOLM1 was detected after TP73-AS1 silencing. As expected, the mRNA and protein expression of GOLM1 was remarkably decreased after silencing TP73-AS1 both in AsPc-1 and Capan-1 cells (Figure 6D). Moreover, the level of GOLM1 mRNA was significantly down-regulated in PC tissues compared to

**A** LncRNA TP73-AS1 **MUT** 5'-CCCTTCGCCAGTCC **GGCAAA**-3'  
 hsa-miR-128-3p 3'-TTTCTCTGGCCAAGTGACACT-5'  
 LncRNA TP73-AS1 **WT** 5'-CCCTTCGCCAGTCCACTGTGA-3'





**Figure 3 TP73-AS1 physically interacts with miR-128-3p-3p.** A: miR-128-3p and its predicted binding sites in the TP73-AS1 sequence; B: Luciferase activity of pancreatic cancer (PC) cells co-transfected with miRNA mimics and luciferase reporter vectors containing TP73-AS1-WT or TP73-AS1-MUT; C: RNA immunoprecipitation assay of the enrichment of TP73-AS1 in AsPc-1 and Capan-1 transfected with miR-NC or miR-128-3p. Immunoglobulin G was used as negative control; D: Expression levels of miR-128-3p in AsPc-1 and Capan-1 cells transfected with si-control or small interfering RNAs targeting TP73-AS1; E: Expression levels of miR-128-3p in PC tissues and adjacent non-tumor tissues; F: The expression of TP73-AS1 and miR-128-3p exhibits a negative correlation in PC tissues. <sup>b</sup>*P* < 0.01. IgG: Immunoglobulin G.


the corresponding non-cancerous tissues (Figure 6E). Interestingly, an inverse correlation was identified between miR-128-3p and GOLM1 mRNA levels in PC tissues (Figure 6F). In contrast, the positive relationship between TP73-AS1 and GOLM1 mRNA levels was observed in PC tissues (Figure 6G). The protein expression of GOLM1 was increased after anti-miR-128-3p transfection in TP73-AS1 silencing PC cells (Figure 6H), which suggested that TP73-AS1 could regulate the expression of GOLM1 by acting as a sponge for miR-128-3p *in vitro*.

#### TP73-AS1 silencing inhibits tumor growth and metastasis of PC cells


To further elucidate the biological roles of TP73-AS1 in PC tumorigenesis *in vivo*, Capan-1 cells transfected with si-TP73-AS1#1 or si-Control were implanted into nude mice *via* subcutaneous injection. Four weeks later, the subcutaneous tumors were collected. Tumor growth curve and tumor weight from the si-TP73-AS1#1 group showed lower size and lighter tumor weight (Figure 7A-C). Moreover, qRT-PCR analysis suggested that the expression of TP73-AS1 was decreased (Figure 7D) and the expression of miR-128-3p (Figure 7E) was increased in the si-TP73-AS1#1 group. In addition, Ki-67 immunostaining indicated that the subcutaneous tumors formed by TP73-AS1 silencing Capan-1 cells showed fewer Ki-67 positive cells compared to the control group (Figure 7F). Together, the *in vitro* and *in vivo* results suggested that TP73-AS1 might function as an oncogene in the progression of PC. To investigate the metastatic potential of TP73-AS1 *in vivo*, Capan-1 cells transfected with si-TP73-AS1#1 or si-Control were injected into the mice *via* the tail vein. As shown in Figure 7G, silencing TP73-AS1 remarkably decreased the number and size of lung metastatic lesions as detected by H&E staining. Moreover, we detected apoptotic markers in the tumors from the two groups and the results showed that apoptosis-related genes were significantly altered (Figure 7H).

## DISCUSSION


Increasing numbers of studies have shown that lncRNAs are involved in both normal development and pathological processes of human diseases by chromatin modification, genomic imprinting, RNA decay, and sponge-like miRNAs[5,18,19]. Dysregulation of lncRNAs might influence cell proliferation, metastasis, angiogenesis, and drug resistance[18,20,21]. It has been previously reported that increased expression of TP73-AS1 is associated with a poorer prognosis and shorter survival in patients with hepatocellular carcinoma[13]. High TP73-AS1 expression was also observed and associated with poor overall survival of patients with osteosarcoma[22]. TP73-AS1 was up-regulated in both colorectal cancer tissues and colorectal cancer cells




**D**



**E**



**F**



**Figure 4** MiR-128-3p inhibits the proliferation, migration, and invasion of pancreatic cancer cells. A: The efficiencies of overexpression for miR-128-3p determined by quantitative real-time polymerase chain reaction; B and C: CCK-8 assay (B) and colony formation assay (C) for detecting cell proliferative ability after overexpression of miR-128-3p; D: Effect of miR-128-3p on pancreatic cancer cell apoptosis determined by flow cytometry; E and F: Transwell assay with or without matrigel for assessing the effect of miR-128-3p on cell migration and invasion in AsPc-1 (E) and Capan-1 (F) cells. <sup>b</sup>P < 0.01.

and high TP73-AS1 expression was associated with metastasis and advanced clinical stages in patients with colorectal cancer[23]. Above studies suggested that TP73-AS1 might act as an oncogene in tumor progression, which encouraged us to explore the expression and biological function of TP73-AS1 in PC. In agreement with these studies, we found that TP73-AS1 was significantly increased and associated with tumor size, vessel infiltration, and poor prognosis in PC patients. Furthermore, our results showed that knockdown of TP73-AS1 suppressed the proliferation and invasion of PC cells *in vitro* and the tumor growth *in vivo*.


Emerging studies demonstrated that lncRNAs could function as ceRNAs to regulate gene expression through competitively binding to miRNAs[4,5]. To further investigate the mechanism of the TP73-AS1 in PC, bioinformatics analysis predicted that TP73-AS1 is a target of miR-128-3p. Numerous studies have indicated that miR-128-3p could act as a tumor suppressive role in many tumors, including glioma, breast cancer, and non-small cell lung cancer[24-26]. In our present study, we found that miR-128-3p could significantly suppress PC cell growth and invasion. Luciferase reporter assay confirmed the relationship between TP73-AS1 and miR-128-3p. Mechanistical study showed that TP73-AS1 could mediate PC cell proliferation, migration, and invasion by sponging miR-128-3p and a negative correlation between TP73-AS1 and miR-128-3p expression was observed in PC tissues. Further investigation indicated that the 3'UTR of *GOLM1* harbors a functional response element for miR-128-3p. *GOLM1*, a type II transmembrane protein, has been reported to be induced by virus infection[27,28]. Recent studies have shown that *GOLM1* commonly expressed in epithelial cells of normal tissues was significantly upregulated in tumor tissues, which suggested a possible oncogenic role of *GOLM1* in tumor progression[29,30]. Moreover, clinicopathological features showed that *GOLM1* was correlated with Edmondson grade, vascular invasion, TNM stage, overall survival, as well as Vimentin expression[31]. *GOLM1* was also reported to promote prostate cancer cell growth, migration, and invasion, and inhibited cell apoptosis *via* the PI3K/AKT/mTOR signaling axis[32]. The role of *GOLM1* was unclear in PC and our data showed that the mRNA expression of *GOLM1* was increased in PC tissues. Moreover, ectopic expression of miR-128-3p significantly inhibited the expression of *GOLM1* at both the mRNA and protein level. Most interestingly, miR-128-3p-3p could abrogate TP73-AS1-mediated expression of *GOLM1*, which suggested that TP73-AS1 could act as a molecular sponge to decrease miR-128-3p expression, thereby resulting in partial abolition of the translational repression of its target gene *GOLM1* in PC cells.

*KRAS* gene, the most common genetic driver in PC, is mutated in about 93% of PC s[33,34]. The *KRAS* protein is a small GTPase, which is responsible for interacting with cell membrane growth factor receptors and controlling the switch of multiple signaling pathways and cellular processes. Oncogenic *KRAS* mutations have been found in 95% of pancreatic ductal adenocarcinoma tissues[35,36]. Decades of research have discovered and clarified the complex picture of *KRAS*-regulated biological processes, including cell metabolism, tumor cell signaling, the tumor microenvironment, micropinocytosis, apoptosis, and redox homeostasis[37,38]. In our research, ASPC-1 and Capan-1 cells were the two PC cell lines that we selected, both of which contained mutations in the *KRAS* gene. As our results show, the regulatory roles of TP73-AS1 in cell proliferation, migration, and invasion ability were verified by Cell Counting Kit-8, wound-healing, and transwell assays in ASPC-1 and Capan-1 cells. Due to the vital role that *KRAS* could play in PC, we are also curious about the role of TP73-AS1 in *KRAS* wild cells. Therefore, in our further research, we would select BXPc-3 cell line, which contains wild *KRAS* gene, for *in vitro* and *in vivo* functional assays of TP73-AS1 to detect whether *KRAS* gene could modulate the function of TP73-AS1 in PC.


## CONCLUSION

In summary, our data suggested that TP73-AS1 could function as an oncogenic lncRNA in PC progression. Moreover, TP73-AS1 could promote tumor growth and invasion by acting as a ceRNA to promote *GOLM1* expression by sponging miR-128-3p in PC.


**A**




**B**



**C**






**Figure 5** MiR-128-3p is responsible for TP73-AS1-mediated malignant behavior. A: Knockdown of miR-128-3p eliminates the inhibition on cell proliferation by TP73-AS1 depletion; B: Depletion of miR-128-3p abolishes cell apoptosis induced by TP73-AS1 silencing; C and D: Representative images of migrated and invaded cells treated with si-TP73-AS1#1 and anti-miR-NC or anti-miR-128-3p in AsPc-1 (C) and Capan-1 (D) cells; E: Epithelial-mesenchymal transition-related proteins detected by Western blot. <sup>a</sup> $P < 0.05$ ; <sup>b</sup> $P < 0.01$ . GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.


**A**

GOLM1 3' UTR MUT 5'-GACTGAATACTGAAAA GGGCCC A-3'  
 hsa-miR-128-3p 3'-TTTCTCTGGCCAAGTGACACT-5'  
 |||||  
 GOLM1 3' UTR WT 5'-GACTGAATACTGAAAACTGTGAA-3'


**B**




**C**





**D**





**Figure 6 TP73-AS1 increases GOLM1 expression by decreasing miR-128-3p.** A: Schematic diagram presenting the putative miR-128-3p recognition site in the GOLM1 sequence; B: Luciferase activity in pancreatic cancer (PC) cells transfected with miR-128-3p and reporter plasmids containing WT or MUT GOLM1 3'UTR; C: The GOLM1 mRNA (up) and protein (down) levels in AsPc-1 and Capan-1 cells with miR-128-3p transfection; D: The GOLM1 mRNA (up) and protein (down) levels in AsPc-1 and Capan-1 cells after TP73-AS1 silencing; E: The expression levels of *GOLM1* mRNA in 116 pairs of PC and adjacent non-tumor tissues assessed by quantitative real-time polymerase chain reaction; F: The relationship between miR-128-3p and *GOLM1* mRNA levels assessed by Pearson correlation analysis; G: The relationship between TP73-AS1 and *GOLM1* mRNA levels assessed by Pearson correlation analysis; H: The protein expression levels of *GOLM1* detected by Western blot assay as indicated. <sup>b</sup> $P < 0.01$ . GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.





**Figure 7 TP73-AS1 knockdown inhibits tumor growth and metastasis in nude mice.** A: Images of resected tumors from nude mice from the indicated groups.  $n = 5$  mice per group; B: Tumor growth curves established by measuring tumor volume after injection at the indicated time points; C: Weights of resected tumors from nude mice from the indicated groups; D and E: Quantitative real-time polymerase chain reaction to detect the expression of TP73-AS1 (D) and miR-128-3p (E) in xenograft tumor tissues; F: Ki67 expression in resected tumor tissues evaluated by immunohistochemistry analysis; G: Representative images and quantification of hematoxylin and eosin staining of lungs isolated from mice; H: Apoptosis markers detected by Western blot. <sup>b</sup> $P < 0.01$ . GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

## ARTICLE HIGHLIGHTS

### Research background

Pancreatic cancer (PC) is the fourth most frequent cause of cancer-related deaths in the world. Emerging evidence has revealed that long non-coding RNAs (lncRNAs) could play crucial roles in the progression of PC. However, the biological role and clinical significance of TP73-AS1 in PC remain unclear.

### Research motivation

Treatments for PC are still limited, and surgical resection could be the only chance to obtain curative treatment. We hope to provide a novel therapeutic target for patients with PC.

### Research objectives

The present study aimed to investigate the role of TP73-AS1 in the growth and metastasis of PC.

### Research methods

Quantitative reverse transcription-polymerase chain reaction was used to detect the expression of lncRNA TP73-AS1, miR-128-3p, and *GOLM1* in PC tissues and cells. The regulatory roles of TP73-AS1 in cell proliferation, migration, and invasion ability were verified by Cell Counting Kit-8, wound-healing, and transwell assays. The bioinformatics prediction software ENCORI was used to predict the putative binding sites of miR-128-3p. The interactions among TP73-AS1, miR-128-3p, and *GOLM1* were explored by bioinformatics prediction, luciferase assay, and Western blot.

### Research results

Our data suggested that TP73-AS1 and miRNA-128-3p were dysregulated in PC tissues and cells. TP73-AS1 silencing inhibited PC cell proliferation, migration, and invasion *in vitro* as well as suppressed tumor growth *in vivo*. Moreover, TP73-AS1

could promote tumor growth and invasion by acting as a competing endogenous RNA to promote GOLM1 expression by sponging miR-128-3p in PC.

### Research conclusions

TP73-AS1 could promote PC cell proliferation and metastasis by modulating the miR-128-3p/GOLM1 axis.

### Research perspectives

TP73-AS1 could promote PC progression, which might provide a potential treatment strategy for patients with PC.

## REFERENCES

- 1 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin* 2014; **64**: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208]
- 2 Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. *Lancet* 2016; **388**: 73-85 [PMID: 26830752 DOI: 10.1016/S0140-6736(16)00141-0]
- 3 Tsai S, Evans DB. Therapeutic Advances in Localized Pancreatic Cancer. *JAMA Surg* 2016; **151**: 862-868 [PMID: 27276001 DOI: 10.1001/jamasurg.2016.1113]
- 4 Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. *Nature* 2013; **495**: 384-388 [PMID: 23446346 DOI: 10.1038/nature11993]
- 5 Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. *Mol Cell* 2011; **43**: 904-914 [PMID: 21925379 DOI: 10.1016/j.molcel.2011.08.018]
- 6 Ebahimzadeh K, Shoorei H, Mousavinejad SA, Anamag FT, Dinger ME, Taheri M, Ghafouri-Fard S. Emerging role of non-coding RNAs in response of cancer cells to radiotherapy. *Pathol Res Pract* 2021; **218**: 153327 [PMID: 33422780 DOI: 10.1016/j.prp.2020.153327]
- 7 Wang C, Chen Y, Chen K, Zhang L. Long Noncoding RNA LINC01134 Promotes Hepatocellular Carcinoma Metastasis via Activating AKT1S1 and NF- $\kappa$ B Signaling. *Front Cell Dev Biol* 2020; **8**: 429 [PMID: 32656205 DOI: 10.3389/fcell.2020.00429]
- 8 Duguang L, Jin H, Xiaowei Q, Peng X, Xiaodong W, Zhennan L, Jianjun Q, Jie Y. The involvement of lncRNAs in the development and progression of pancreatic cancer. *Cancer Biol Ther* 2017; **18**: 927-936 [PMID: 29053398 DOI: 10.1080/15384047.2017.1385682]
- 9 Chen X, Wang J, Xie F, Mou T, Zhong P, Hua H, Liu P, Yang Q. Long noncoding RNA LINC01559 promotes pancreatic cancer progression by acting as a competing endogenous RNA of miR-1343-3p to upregulate RAF1 expression. *Aging (Albany NY)* 2020; **12**: 14452-14466 [PMID: 32678071 DOI: 10.18632/aging.103487]
- 10 Deng SJ, Chen HY, Ye Z, Deng SC, Zhu S, Zeng Z, He C, Liu ML, Huang K, Zhong JX, Xu FY, Li Q, Liu Y, Wang CY, Zhao G. Hypoxia-induced lncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. *Oncogene* 2018; **37**: 5811-5828 [PMID: 29970904 DOI: 10.1038/s41388-018-0382-1]
- 11 You L, Chang D, Du HZ, Zhao YP. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. *Biochem Biophys Res Commun* 2011; **407**: 1-6 [PMID: 21316338 DOI: 10.1016/j.bbrc.2011.02.027]
- 12 Zhang R, Jin H, Lou F. The Long Non-Coding RNA TP73-AS1 Interacted With miR-142 to Modulate Brain Glioma Growth Through HMGB1/RAGE Pathway. *J Cell Biochem* 2018; **119**: 3007-3016 [PMID: 28379612 DOI: 10.1002/jcb.26021]
- 13 Li S, Huang Y, Fu Y, Tang D, Kang R, Zhou R, Fan XG. The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation. *J Exp Clin Cancer Res* 2017; **36**: 51 [PMID: 28403886 DOI: 10.1186/s13046-017-0519-z]
- 14 Zhang L, Fang F, He X. Long noncoding RNA TP73-AS1 promotes non-small cell lung cancer progression by competitively sponging miR-449a/EZH2. *Biomed Pharmacother* 2018; **104**: 705-711 [PMID: 29803931 DOI: 10.1016/j.biopha.2018.05.089]
- 15 Deng B, Wang B, Fang J, Zhu X, Cao Z, Lin Q, Zhou L, Sun X. MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2. *Sci Rep* 2016; **6**: 28301 [PMID: 27376958 DOI: 10.1038/srep28301]
- 16 Jiang J, Feng X, Zhou W, Wu Y, Yang Y. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway. *Oncotarget* 2016; **7**: 73188-73199 [PMID: 27690301 DOI: 10.18632/oncotarget.12283]
- 17 Liu T, Zhang X, Du L, Wang Y, Liu X, Tian H, Wang L, Li P, Zhao Y, Duan W, Xie Y, Sun Z, Wang C. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer. *Mol Cancer* 2019; **18**: 43 [PMID: 30890168 DOI: 10.1186/s12943-019-0981-7]
- 18 Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. *Cell* 2013; **152**: 1298-1307 [PMID: 23498938 DOI: 10.1016/j.cell.2013.02.012]
- 19 Li N, Yang G, Luo L, Ling L, Wang X, Shi L, Lan J, Jia X, Zhang Q, Long Z, Liu J, Hu W, He Z, Liu H, Liu W, Zheng G. lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and

- Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP. *Clin Cancer Res* 2020; **26**: 1736-1748 [PMID: [31831555](#) DOI: [10.1158/1078-0432.CCR-19-0674](#)]
- 20 **Pan S**, Shen M, Zhou M, Shi X, He R, Yin T, Wang M, Guo X, Qin R. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. *Cell Death Dis* 2019; **10**: 883 [PMID: [31767833](#) DOI: [10.1038/s41419-019-2123-y](#)]
  - 21 **Kong X**, Liu CX, Wang GD, Yang H, Yao XM, Hua Q, Li XY, Zhang HM, Ma MZ, Su Q, Lv K. LncRNA LEGLTBC Functions as a ceRNA to Antagonize the Effects of miR-34a on the Downregulation of SIRT1 in Glucolipotoxicity-Induced INS-1 Beta Cell Oxidative Stress and Apoptosis. *Oxid Med Cell Longev* 2019; **2019**: 4010764 [PMID: [31737170](#) DOI: [10.1155/2019/4010764](#)]
  - 22 **Yang G**, Song R, Wang L, Wu X. Knockdown of long non-coding RNA TP73-AS1 inhibits osteosarcoma cell proliferation and invasion through sponging miR-142. *Biomed Pharmacother* 2018; **103**: 1238-1245 [PMID: [29864904](#) DOI: [10.1016/j.biopha.2018.04.146](#)]
  - 23 **Cai Y**, Yan P, Zhang G, Yang W, Wang H, Cheng X. Long non-coding RNA TP73-AS1 sponges miR-194 to promote colorectal cancer cell proliferation, migration and invasion via up-regulating TGF $\alpha$ . *Cancer Biomark* 2018; **23**: 145-156 [PMID: [30010111](#) DOI: [10.3233/CBM-181503](#)]
  - 24 **Papagiannakopoulos T**, Friedmann-Morvinski D, Neveu P, Dugas JC, Gill RM, Huillard E, Liu C, Zong H, Rowitch DH, Barres BA, Verma IM, Kosik KS. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. *Oncogene* 2012; **31**: 1884-1895 [PMID: [21874051](#) DOI: [10.1038/onc.2011.380](#)]
  - 25 **Zhu Y**, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y, Song E. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. *Clin Cancer Res* 2011; **17**: 7105-7115 [PMID: [21953503](#) DOI: [10.1158/1078-0432.CCR-11-0071](#)]
  - 26 **Cai J**, Fang L, Huang Y, Li R, Xu X, Hu Z, Zhang L, Yang Y, Zhu X, Zhang H, Wu J, Li J, Zeng M, Song E, He Y, Li M. Simultaneous overactivation of Wnt/ $\beta$ -catenin and TGF $\beta$  signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. *Nat Commun* 2017; **8**: 15870 [PMID: [28627514](#) DOI: [10.1038/ncomms15870](#)]
  - 27 **Wei H**, Hao X, Li B, Li X, Hou J, Qiao Y, Zhang R. GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy. *Mol Biol Rep* 2013; **40**: 6397-6405 [PMID: [24068434](#) DOI: [10.1007/s11033-013-2754-5](#)]
  - 28 **Kladney RD**, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. *Hepatology* 2002; **35**: 1431-1440 [PMID: [12029628](#) DOI: [10.1053/jhep.2002.32525](#)]
  - 29 **Mao Y**, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, Yang Z, Cai J, Li H, Chen J, Zhong S, Mohanti SR, Lopez-Soler R, Millis JM, Huang J, Zhang H. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. *Gut* 2010; **59**: 1687-1693 [PMID: [20876776](#) DOI: [10.1136/gut.2010.214916](#)]
  - 30 **Ye QH**, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, Guo L, Zhang B, Lin ZH, Roessler S, Forgues M, Jia HL, Lu L, Zhang XF, Lian BF, Xie L, Dong QZ, Tang ZY, Wang XW, Qin LX. GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis. *Cancer Cell* 2016; **30**: 444-458 [PMID: [27569582](#) DOI: [10.1016/j.ccell.2016.07.017](#)]
  - 31 **Bao YX**, Cao Q, Yang Y, Mao R, Xiao L, Zhang H, Zhao HR, Wen H. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). *Diagn Pathol* 2013; **8**: 197 [PMID: [24313979](#) DOI: [10.1186/1746-1596-8-197](#)]
  - 32 **Yan G**, Ru Y, Wu K, Yan F, Wang Q, Wang J, Pan T, Zhang M, Han H, Li X, Zou L. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling. *Prostate* 2018; **78**: 166-177 [PMID: [29181846](#) DOI: [10.1002/pros.23461](#)]
  - 33 **Haigis KM**. KRAS Alleles: The Devil Is in the Detail. *Trends Cancer* 2017; **3**: 686-697 [PMID: [28958387](#) DOI: [10.1016/j.trecan.2017.08.006](#)]
  - 34 **di Magliano MP**, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. *Gastroenterology* 2013; **144**: 1220-1229 [PMID: [23622131](#) DOI: [10.1053/j.gastro.2013.01.071](#)]
  - 35 **Jones S**, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; **321**: 1801-1806 [PMID: [18772397](#) DOI: [10.1126/science.1164368](#)]
  - 36 **Ryan DP**, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. *N Engl J Med* 2014; **371**: 2140-2141 [PMID: [25427123](#) DOI: [10.1056/NEJMc1412266](#)]
  - 37 **Tape CJ**, Ling S, Dimitriadis M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulgiannis G, Lauffenburger DA, Jørgensen C. Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocity. *Cell* 2016; **165**: 1818 [PMID: [27315484](#) DOI: [10.1016/j.cell.2016.05.079](#)]
  - 38 **Liang C**, Qin Y, Zhang B, Ji S, Shi S, Xu W, Liu J, Xiang J, Liang D, Hu Q, Ni Q, Xu J, Yu X. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. *Biochim Biophys Acta* 2016; **1866**: 177-188 [PMID: [27600832](#) DOI: [10.1016/j.bbcan.2016.09.001](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

